| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA791: Romosozumab for treating severe osteoporosis |
|
Medicine details |
|
| Medicine name | romosozumab (Evenity®) |
| Formulation | 105 mg solution for injection |
| Reference number | 1144 |
| Indication | Treatment of severe osteoporosis in postmenopausal women at high risk of fracture |
| Company | UCB Pharma Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/02/2020 |
| NICE guidance | |
| Commercial arrangement | PAS |